Investegate |Tissue Regenix Group Announcements | Tissue Reg

Investegate |Tissue Regenix Group Announcements | Tissue Regenix Group: Issue of Equity & Total Voting Rights Replacement


About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

Related Keywords

Ben Maddison Alex , Caitlin Pearson , Head Of Communications , Stifel Nicolaus Europe Limited Nominated Adviser , Tissue Regenix Group , Total Voting Rights , Regenix Group , Nicolaus Europe Limited , Nominated Adviser , Tissue Regenix , Cellright Technologies , பென் மாடிசன் அலெக்ஸ் , கெய்ட்லின் பியர்சன் , தலை ஆஃப் தகவல்தொடர்புகள் , திசு ரேகேனீக்ஷ குழு , மொத்தம் வாக்களித்தல் உரிமைகள் , ரேகேனீக்ஷ குழு , நிக்கோலஸ் யூரோப் வரையறுக்கப்பட்டவை , திசு ரேகேனீக்ஷ ,

© 2025 Vimarsana